U.S. markets closed

  • S&P 500

    4,352.34
    +32.40 (+0.75%)
     

  • Dow 30

    34,786.35
    +152.85 (+0.44%)
     

  • Nasdaq

    14,639.33
    +116.92 (+0.81%)
     

  • Russell 2000

    2,305.76
    -23.60 (-1.01%)
     

  • Crude Oil

    75.28
    +0.12 (+0.16%)
     

  • Gold

    1,789.10
    +5.80 (+0.33%)
     

  • Silver

    26.58
    +0.10 (+0.39%)
     

  • EUR/USD

    1.1867
    -0.0006 (-0.05%)
     

  • 10-Yr Bond

    1.4310
    -0.0490 (-3.31%)
     

  • GBP/USD

    1.3845
    +0.0018 (+0.13%)
     

  • USD/JPY

    110.9940
    -0.0460 (-0.04%)
     

  • BTC-USD

    34,315.35
    -954.08 (-2.71%)
     

  • CMC Crypto 200

    856.70
    +47.15 (+5.82%)
     

  • FTSE 100

    7,123.27
    -1.89 (-0.03%)
     

  • Nikkei 225

    28,598.19
    -185.09 (-0.64%)
     

Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement

  • Oops!
    Something went wrong.
    Please try again later.
NICOX
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

Press Release

Nicox to Receive $2 Million from Ocumension Therapeutics as Advance Milestone Payment under ZERVIATE® Agreement



July 5, 2021 – release at 7:30 am CET
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced that it has amended its March 2019 license agreement with Ocumension Therapeutics, under which Ocumension has exclusive rights to develop and commercialize ZERVIATE® (cetirizine ophthalmic solution), 0.24% in the Chinese and the majority of South East Asian markets. Under the amended agreement, Ocumension will immediately pay Nicox $2 million in full advance payment of the future development and regulatory milestones for the product. Amendments were made to certain rights under non-financial clauses of the agreement.

Nicox remains eligible to receive the same sales milestones of up to US$17.2 million together with tiered royalties of between 5% and 9% of net sales of ZERVIATE by Ocumension. ZERVIATE is currently being evaluated in a confirmatory Phase 3 clinical trial in China by Ocumension, to support a Chinese New Drug Application for the treatment of ocular itching associated with allergic conjunctivitis.

ZERVIATE is the first and only topical ocular formulation of the antihistamine cetirizine and has been commercialized in the United States since March 2020 by Nicox’s exclusive U.S. licensee, Eyevance Pharmaceuticals, a wholly-owned subsidiary of Santen (Japan). In addition to Ocumension for the Chinese and the majority South East Asian markets, ZERVIATE is also exclusively licensed to Samil Pharmaceutical in South Korea, to ITROM Pharmaceutical Group in certain Gulf and Arab markets and to Laboratorios Grin for Mexico.

About ZERVIATE

ZERVIATE® (cetirizine ophthalmic solution), 0.24% is a novel formulation of cetirizine developed and approved for the first time for topical application in the eye for the treatment of ocular itching associated with allergic conjunctivitis. Cetirizine, the active ingredient in ZYRTEC®, is a second-generation antihistamine (H1 receptor antagonist) that binds competitively to histamine receptor sites. Cetirizine, in approved oral formulations, has a well-characterized systemic efficacy and safety profile with worldwide exposure resulting from 20 years of oral use. ZERVIATE was developed by Nicox as the first and only formulation of cetirizine for topical application in the eye.

About Allergic Conjunctivitis

Allergic conjunctivitis occurs when an allergic reaction causes conjunctivitis, an inflammation of the thin layer of tissue that lines the outside of the white surface of the eye and the inner surface of the eyelids. It may affect one or both eyes. The signs and symptoms may include eye redness, excessive watering, itchy burning eyes, discharge, blurred vision and increased sensitivity to light.

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating prostaglandin analog, for lowering intraocular pressure in patients with glaucoma. The company is also developing NCX 4251, a proprietary formulation of fluticasone, for acute exacerbations of blepharitis. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC, in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of South East Asian markets.

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage



Bryan, Garnier & Co Victor Floc’h Paris, France
Cantor Fitzgerald Louise Chen New York, U.S.
Edison Investment Research Pooya Hemami London, UK
H.C. Wainwright & Co Yi Chen New York, U.S.
Kepler Cheuvreux Damien Choplain Paris, France

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Contacts

Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media
United States & Europe
LifeSci Advisors, LLC
Mary-Ann Chang
T +44 7483 284 853
mchang@lifesciadvisors.com

Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com



Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2020’ filed with the French Autorité des Marchés Financiers (AMF) on March 1, 2021 which are available on Nicox’s website (www.nicox.com).

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

Attachment


Recommended Stories

  • Beijing’s Blocking of Didi App Sends Peers Tumbling in Hong Kong

    (Bloomberg) -- Shares of Chinese technology companies slid in Hong Kong as investors stepped back to gauge the impact from Beijing’s move to block ride-hailing giant Didi Chuxing from app stores due to data security issues.Tencent Holdings Ltd., which has a stake in Didi, slumped as much as 4.2% in Hong Kong to erase its year-to-date gain. Meituan, ordered by China’s antitrust watchdog to rectify practices in May, lost as much as 5.9%, while the Hang Seng Tech Index slid as much as 2.4% to its l

  • Micron's Costs Are Going Up: Here's Why I'm Buying Anyway

    Despite good long-term growth prospects for memory demand, Micron trades at an enormous discount to the market and especially other tech stocks – even peers in the volatile semiconductor sector. Case in point: Micron's recent earnings report, in which the company posted stellar numbers across the board, while also giving solid guidance. Memory crashes tend to happen when the industry overinvests in supply when demand is good and memory prices are rising, only to have too much capacity when demand hits an air pocket and pulls back.

  • Second-Half 2021: Market Forecasts, Thoughts and Observations

    The stock market has given us some incredible returns in the past year or two but there are some warning signs developing -- and one key date to keep an eye on.

  • Reddit Trading Group WallStreetBets Goes Private: Where Will Retail Traders Go Now?

    Reddit group r/WallStreetBets (WSB) has closed its doors and is now a private-only community. What Happened: Only users who moderators have approved will be able to view the page and take part in discussions. Why This Matters: WallStreetBets is the group that initiated the mega GameStop Corp (NYSE: GME) short squeeze at the end of January. They managed to drive the price of GameStop to over $400 while causing massive damage to hedge funds that shorted it, such as Melvin Capital. WSB stood togeth

  • Buying These 3 Robinhood Stocks Could Be the Smartest Investing Moves You'll Ever Make

    In the book, author James Surowiecki laid out the case that "the many are smarter than the few." Take, for example, Robinhood's 100 most popular list. It includes the stocks most widely held by investors on the trading platform.

  • Get rich as a renter: How to build wealth when you don't want to own a home

    Owning a house isn’t the only pathway to financial success and fulfillment.

  • Lidar Is the Future of Autonomous Driving. This Company Is Making It Cheaper and Better.

    Innoviz, a maker of lidar, the laser-based radar used in self-driving cars, believes it has the right strategy to win market share from competitors.

  • 5 Top Stocks for July

    Here's why they highlighted Ayr Wellness (OTC: AYRW.F), Illumina (NASDAQ: ILMN), Intel (NASDAQ: INTC), Nano-X Imaging (NASDAQ: NNOX), and Fiserv (NASDAQ: FISV) as top opportunities. Todd Campbell (Illumina): Genetics and genomics are reshaping how we diagnose, treat, and manage disease and arguably, no company has contributed more to advances in health enabled by DNA research than Illumina.

  • Jeff Bezos is stepping down as CEO. How rich did Amazon make him?

    No need to check his 401k or social security before retiring. Jeff Bezos, who steps down Monday as Amazon’s CEO, is the world’s richest person.

  • A Whopper of a Stock Buy at Burger King’s Parent

    Shares of Restaurant Brands, the parent of Burger King and Popeyes, have underperformed this year, but new director Marc Lemann bought up stock.

  • 10 Best Roth IRA Stocks to Buy According to Reddit

    In this article, we discuss the 10 best Roth IRA stocks to buy according to Reddit. If you want to skip our detailed analysis of these stocks, go directly to the 5 Best Roth IRA Stocks to Buy According to Reddit. Roth IRA accounts have been an attractive savings vehicle for many Americans over the […]

  • Forget Dogecoin, Buy These 3 High-Growth Tech Stocks Instead

    Dogecoin's (CRYPTO: DOGE) once seemingly unstoppable ride "to the moon," spurred on by the likes of Elon Musk and Mark Cuban, has been knocked off course in the last month. The meme coin is currently down some 68% from all-time highs reached in May. There's no saying whether the fire beneath Dogecoin will be relit -- and when it will happen if so. If you're looking to hedge your bets with other investments that could skyrocket higher, these three Fool.com contributors think Upstart Holdings (NASDAQ: UPST), Newegg Commerce (NASDAQ: NEGG), and Tencent Holdings (OTC: TCEHY) are worth a serious look instead of the cryptocurrency famous for its Shiba Inu mascot.

  • Top S&P 500 Index Funds

    The Standard & Poor's 500 Index, or simply S&P 500, is a market-capitalization-weighted index of 500 large-cap U.S. companies that make up 80% of U.S. equity by market cap. It is widely regarded as the best gauge of large-cap U.

  • What Your 401(k) Could Look Like in the Next 20 Years

    Discover how time and compounded growth of earnings can help even a modest 401(k) balance grow to a significant sum over 20 years.

  • China Widens Security Probe to Two More U.S.-Listed Firms

    (Bloomberg) -- The Chinese government widened its probe of the country’s technology industry to two more U.S.-listed companies, targeting Full Truck Alliance Co. and Kanzhun Ltd. soon after launching a review into Didi Global Inc.The Cyberspace Administration of China said Monday new user registrations at the two companies’ online platforms will be halted during the probe in the interests of preserving national and data security. The move follows a similar action by the CAC to order the removal

  • GM Crushes Ford in Truck Wars but Loses Q2 Sales Crown to Toyota

    The global semiconductor shortage has weighed on auto production this year, constraining U.S. sales despite strong demand. Toyota Motor (NYSE: TM) became the top-selling automaker in the U.S. for the first time ever, edging out General Motors (NYSE: GM).

  • 10 Steps to Retire as a Millionaire

    Making your dream of retiring as a millionaire come true takes work, but it’s well worth the effort.

  • Is It Time to Buy the Dow Jones' 3 Worst-Performing June Stocks?

    A trio of names is suspiciously in the same boat for the same reason, perhaps dropping a hint too big to be ignored.

  • A Biden idea sparks bills that could net new homebuyers tons of cash

    Democrats' proposals would offer tens of thousands of dollars to first-time buyers.

  • Chart a Path to Financial Independence With These Unstoppable Stocks

    When the dust settles, fintech stock Square (NYSE: SQ) should come out as one of the leading providers of cashless/digital payments. While the seller ecosystem has long targeted smaller merchants, GPV trends show that larger merchants (those with annualized GPV above $125,000) now account for a majority of all GPV on the network. Bigger merchants should translate to higher gross profit over time.